MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Dexcom Becomes More Connected with New FDA Clearance

MichaelVi - stock.adobe.com IMG_Jul192021at40833PM.jpg
The San Diego, CA-based company has won a nod for the Dexcom Partner Web APIs to invite third-party developers to integrate real-time continuous glucose monitoring data into their digital health apps and devices.

Dexcom has become more connected than ever with FDA’s latest measure. The watchdog agency has cleared the Dexcom Partner Web APIs to enable third-party developers to integrate real-time continuous glucose monitoring data into their digital health apps and devices.

The San Diego, CA-based company has courted several prominent diabetes and digital health companies to access the real-time APIs that are already in the testing and development phase. These companies include Garmin and Livongo, a firm Teladoc acquired for $18.5 billion.

“FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data,” said Jake Leach, chief technology officer at Dexcom. “The new APIs will help seamlessly integrate the power of real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.”

The integration of the Dexcom CGM data into third-party apps and will allow users to quickly see all their therapy data in one place; empower users to utilize the apps they find most beneficial for a more tailored experience; and enable in-the-moment diabetes management coaching and feedback.

Dexcom is gearing up for its highly anticipated G7 the latest version of the company's popular CGM sensor. During the American Diabetes Association 81st Scientific Sessions, Kevin Sayer, Dexcom's CEO appeared on the Let’s Talk Medtech Podcast to give an update on the technology.

“With our G7 system, we’re literally starting over … it’ll be the most advanced CGM ever built,” Sayer said on the Let’s Talk Medtech Podcast. “Anything, anybody loves about G6, they’re going to like better about G7.”

He added, “We’ve talked about launching in Europe later this year, we haven’t announced a specific time frame. With respect to the U.S., there’s a large pivotal study required to meet the ICgm standards FDA has set. We have not submitted G7 [for FDA] approval yet. We are comfortable that we will get an approval based on our data, but there are a lot of variables in that, that’s why we’re a little vague on the timeframe.”

 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish